Researching IPF after her late husband's diagnosis meant learning many new acronyms and abbreviations, says guest writer.

An Oklahoma City woman was given a few years to live in 2022, after being diagnosed with a serious lung disease. However, ...

Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

A metro woman was given a few years to live in 2022, after being diagnosed with a serious lung disease. However, thanks to a double lung transplant, she was given a second chance at life.

A recent study validates that combining genetic and clinical data can predict the risk for pulmonary fibrosis in patients ...

The 2026 version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report has been published. Key ...

For some patients with the most common type of lung cancer, known as lung adenocarcinoma, there's new hope. In a new study ...

Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

An Oklahoma City woman who was once told she was too old for a lung transplant is now celebrating a second chance at life after receiving a lifesaving double lung transplant.

“Sarcopenia is prevalent among patients with ELD, with its prevalence varying across different populations due to multiple influencing factors, resulting in distinct clinical outcomes,” wrote lead ...

Under current screening guidelines, almost two-thirds of Americans with lung cancer would not have qualified for required scans, researchers said.